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Objectives: The long term effects (.20 years) of anabolic-androgenic steroid (AAS) use on plasma
concentrations of homocysteine (HCY), folate, testosterone, sex hormone binding globulin (SHBG), free
androgen index, urea, creatinine, haematocrit (HCT), vitamin B12, and urinary testosterone/
epitestosterone (T/E) ratio, were examined in a cohort of self-prescribing bodybuilders.
Methods: Subjects (n = 40) were divided into four distinct groups: (1) AAS users still using AAS (SU;
n = 10); (2) AAS users abstinent from AAS administration for 3 months (SA; n = 10); (3) non-drug using
bodybuilding controls (BC; n = 10); and (4) sedentary male controls (SC; n = 10).
Results: HCY levels were significantly higher in SU compared with BC and SC (p,0.01), and with SA
(p,0.05). Fat free mass was significantly higher in both groups of AAS users (p,0.01). Daily energy
intake (kJ) and daily protein intake (g/day) were significantly higher in SU and SA (p,0.05) compared
with BC and SC, but were unlikely to be responsible for the observed HCY increases. HCT concentrations
were significantly higher in the SU group (p,0.01). A significant linear inverse relationship was observed
in the SU group between SHBG and HCY (r =20.828, p,0.01), indicating a possible influence of the sex
hormones in determining HCY levels.
Conclusions: With mounting evidence linking AAS to adverse effects on some clotting factors, the
significantly higher levels of HCY and HCT observed in the SU group suggest long term AAS users have
increased risk of future thromboembolic events.
S
udden death and acute thrombotic events may represent
under-appreciated risks of anabolic-androgenic steroid
(AAS) use and therefore may be under-reported in the
medical literature.1 AAS are known to affect the haemostatic
system,2 3 and systemic emboli and thrombotic complications
have been reported in several androgen using athletes.4–6
Recently, homocysteine (HCY), a by product of methionine
metabolism, has been implicated in various cardiovascular
related diseases. Several studies have established that the
association between plasma HCY concentration and the risk
of cardiovascular disease or severity of atherosclerosis is
graded throughout the normal range from mild to elevated
concentrations.7 8 HCY has been shown to dramatically
impair vascular endothelial function through impairment of
nitric oxide production potentiating oxidative stress and
atherogenic development.9 10 Thus, one would suspect that
elevated HCY levels may play a role in the development of
systemic emboli and thrombotic complications in AAS users.
However, few studies have looked at the effect of androgen
use on HCY production. Zmuda et al11 showed that short term
administration of supraphysiological doses of testosterone
enanthate (200 mg/week) did not affect fasting HCY levels in
14 weightlifters. In contrast, a more recent study identified
acute hyperhomocysteinaemia in bodybuilders regularly self-
administering supraphysiological doses of various AAS
preparations.12
Possible mechanisms for accelerated cardiovascular disease
with elevated HCY include endothelial cell injury,13 increased
platelet adhesiveness,14 enhanced oxidation of LDL in the
arterial cell wall,15 and through direct activation of the
coagulation cascade.16
The hypothesis of the present investigation was that AAS
use significantly elevated plasma HCY concentrations in a
cohort of long term (.20 years) AAS users. A secondary aim
was to compare the findings with age matched control groups
consisting of previous AAS using (but now abstinent)
subjects versus resistance trained non-drug using subjects
and sedentary controls. In addition to plasma concentrations
of HCY, plasma folate, testosterone, sex hormone binding
globulin (SHBG), free androgen index (FAI), urea, creatinine,
haematocrit (HCT), and vitamin B12 (B12) were also
measured. Deficiencies in plasma folate and B12 have been
shown to lead to elevated HCY concentrations. Urinalysis for
AAS was performed and the testosterone/epitestosterone (T/
E) ratio was measured to confirm or refute the use of these
substances. Finally, this study also examined the influence of
sex hormones in determining HCY concentrations and
outlined the possibility of long term AAS users developing
future thromboembolic events.
METHODS
Ethical approval for the study was obtained from the
university ethical committee and all subjects involved, having
read experimental details, provided written consent. AAS
using participants were recruited from a database of subjects
who had been involved in previous studies,17 and from
notices placed on bodybuilding web sites. Each AAS using
recruit provided information stating that they had used AAS
Abbreviations: AAS, anabolic-androgenic steroid; B12, vitamin B12;
BC, bodybuilding controls; FAI, free androgen index; FFM, fat free mass;
FFMI, fat free mass index; HCT, haematocrit; HCY, homocysteine; ROS,
reactive oxygen species; SA, AAS abstinent subjects; SC, sedentary
controls; SD, standard deviation; SHBG, sex hormone binding globulin;
SU, AAS using subjects; TBM, total body mass; T/E, testosterone/
epitestosterone; tHCY, total HCY
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in various doses in cyclical fashion over the previous 20 years
(table 1).
The sample comprised of past and present, amateur,
national, and international bodybuilding competitors. Only
10 of the 30 contacted subjects using AAS agreed to
participate in this study because of the inherent underground
and secretive nature of the activity. Subjects were divided
into four distinct groups: AAS users who were still using AAS
at the time of testing (SU; n = 10), AAS users who had been
abstinent for more than 3 months (SA; n = 10), bodybuilding
controls who did not use any pharmacological ergogenic aids
(BC; n = 10), and sedentary male controls (SC; n = 10). The
SA group had abstained from AAS use for a minimum of
12 weeks prior to examination. The power of the test was
calculated to determine a confidence interval of 95%, p,0.05,
for 10 subjects in each group. Urinalysis was performed in the
IOC accredited laboratory, Drug Control Centre, Kings
College London, UK, to provide confirmation of AAS use in
all groups and to eliminate potential positive samples.
Subjects presenting with positive urine samples were
included solely in the SU cohort. T/E ratios in the SU group
greatly exceeded legal levels for athletic competition. AAS
metabolites for the SU group are outlined in table 2,
demonstrating polypharmacy.
Each subject recorded the quantity and type of food and
beverages ingested for a randomly assigned 3 day period.
This information was analysed for protein concentrations to
determine if creatinine levels had been affected by each
subject’s protein intake (CompEat, Grantham, UK). Total
body mass (TBM) was measured using a balanced weighing
scales (Seca, Cardiokinetics, Salford, UK) and height using a
stadiometer (Seca). Body mass index (BMI) was calculated
by dividing subject weight in kilograms by the square of the
subject’s height in metres. Body fat percentage was deter-
mined using hydrostatic weighing. Following a familiarisa-
tion trial, underwater weight was determined five times. The
mean of the five trials was used as the criterion value. Body
density was determined using the equations of Siri,18 and
percentage fat values calculated using the equation of Durnin
and Womersley.19 Fat free mass (FFM) was calculated by
subtracting fat mass from TBM. Fat free mass index (FFMI)
was calculated by dividing the subject’s FFM in kilograms by
the square of the subject’s height in metres.
Venous blood was sampled using the standard venepunc-
ture method, from an antecubital vein following an overnight
fast and 30 min supine rest.20 Morning blood samples were
taken (between the hours of 10.00 a.m. and 11.00 a.m.) to
minimise the effect of day time biological variation in male
sex hormone concentrations.21 Blood samples were appro-
priately sampled, centrifuged, and immediately stored at
270 C˚ until analysis. Testosterone was analysed on a Bayer
Advia Centaur immunoassay analyser, employing chemilu-
minescence detection (Bayer Diagnostics, Newbury, Berks,
UK). The intra- and inter-assay coefficients of variation for
testosterone were each 7.4%. SHBG and FAI were determined
by enzyme immunoassay (IDS, Boldon, Tyne & Wear, UK).
The intra- and inter-assay coefficients of variation for SHBG
were 0.6% and 1.6%, respectively.
Urea and creatinine were analysed using dry chemistry
slide technology on an Ortho Vitros 950 analyser (Ortho
Clinical Diagnostics, Amersham, Bucks, UK). The intra- and
inter-assay coefficients of variation for creatinine were each
1.8%.
Haematology analyses were performed using a Beckman
Coulter GEN-S (Beckman Coulter, High Wycombe, Bucks,
UK). Total HCY (tHCY) was measured from plasma blood
samples by fluorescence polarisation immunoassay using the
IMx system analyser (Abbott Laboratories, Maidenhead,
UK). The intra- and inter-assay coefficients of variation for
HCY were each 3.6%.
B12 and folate were analysed using microparticle enzyme
immunoassay technology using the IMx system (Abbott
Laboratories). The coefficients of variation for B12 and folate
were each 3.3%.
Statistical analysis
Data were analysed using the SPSS 10.0 for Windows
statistical package. Group differences were analysed using a
one way ANOVA followed by a post-hoc Tukey test. The
Pearson product bivariate procedure was used to examine
correlations between variables. Statistical significance was
accepted at the p,0.05 level. The data are presented as
means¡standard deviation (SD).
RESULTS
Values for BMI, FFM, and FFMI were not different between
SU and SA, but were significantly higher in both AAS using
groups than in BC and SC (p,0.01). The SC group had a
Table 1 Anthropometric characteristics and drug history of subjects
SU SA BC SC
Age (years) 42.4¡3.8 41.7¡3.0 43.1¡4.6 43.8¡4.7
Height (m) 1.78¡4.5 1.76¡3.9 1.80¡3.1 1.76¡4..9
Body mass (kg) 109¡13.2 107¡7.7 91¡7.4 84¡13.4
BMI (kg/m2) 34.4¡2.7** 34.7¡3.7** 28.3¡2.0 27.0¡2.6
Body fat (%) 14.0¡3.4 14.7¡3.8 14.7¡1.4 18.7¡5.6
FFM (kg) 94¡12.1** 91¡11.3** 77¡8.2 67¡7.8
FFMI (kg/m2) 29.6¡2.9** 29.4¡3.5** 23.8¡2.3 21.6¡3.6
Training (years) 25.4¡2.1 22¡3.5 18.5¡2.3 0
AAS use (years) 21¡2.1 20.7¡2.8 0 0
Values are means¡SD. AAS, anabolic-androgenic steroids; BC, bodybuilding controls; BMI, body mass index; FFM, fat free mass; FFMI, fat free mass index; SA,
AAS abstinent subjects; SC, sedentary controls; SU, AAS using subjects.
*p,0.05, significantly greater than BC; **p,0.01, significantly greater than SC; p,0.05, significantly greater than SU, SA, and BC.
Table 2 Various preparations used by the SU group at
the time of testing, as identified in training diaries
Steroid No. of users (n = 10)





Primobolin (methenolone enanthate) 5
Equipoise (boldenone) 2
Finajet (trenbolone) 1
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significantly higher percentage of body fat than the body-
building groups (table 2).
Testosterone was significantly higher in SU (p,0.05)
compared with SA, BC, and SC. SHBG was significantly
lower in SU (p,0.01) compared with the three other groups.
SHBG was also significantly lower in SA (p,0.05) compared
with BC and SC. FAI was significantly higher in the SU group
compared with the three other groups (p,0.001) (table 3).
HCY was significantly higher in SU (p,0.01) and SA
(p,0.05) compared with BC and SC. HCT was significantly
higher in SU compared with BC and SC (p,0.01).
Creatinine was significantly lower in SC compared with SU
(p,0.01) and with SA (p,0.05), but not with BC; SU and SA
were just outside the reference range. Levels of B12, folate,
and urea were not significantly different between groups. The
normal urea indicated that subjects were euhydrated
(table 4).
Daily energy intake (kJ) and daily protein intake (g/day)
were significantly higher (p,0.05) in SU and SA compared
with BC and SC.
Pearson product correlation analyses were subsequently
performed to further assess similarities and differences in
plasma and serum chemistry profiles, first by pooling the
subject groups and then by examining individual group
correlations.
HCY and SHBG demonstrated a significant inverse
relationship in both AAS using groups but not with controls
(SU: r =20.828, p,0.01; SA: r = 0.602, p,0.05). A signifi-
cant relationship was also demonstrated between HCY and
creatinine solely in SU (r = 0.602, p,0.05). Correlation
analyses also revealed a significant relationship between
creatinine and FFM when combining the groups (r = 0.708,
p,0.01), and when assessed individually for SU (r = 0.664,
p,0.05), SA (r = 0.710, p,0.01), and SC (r = 0.743, p,0.05),
but not for BC.
DISCUSSION
The elevated HCY levels observed in the SU group is
consistent with recent work12 but does not agree with the
lack of HCY alteration reported in males treated with
supraphysiological doses of testosterone.11 Differences may
be due to the fact that Zmuda and colleagues administered
therapeutic doses of testosterone enanthate for 3 weeks.
Such a relatively brief intervention may not be sufficient to
elicit augmentation of HCY. In addition, the particular drug
used by Zmuda and co-workers (testosterone enanthate) may
not affect HCY levels to the same extent as the multi-drug
regimen, including ingestion of oral 17-a-alylated AAS, used
in this study and that used in the study of Ebenbichler et al.12
Dietary differences may have also existed between the
bodybuilding and weightlifting groups in these studies. The
significantly higher levels of SHBG in the SA group compared
with both BC and SC indicates prolonged suppression of the
globulin fraction following AAS withdrawal. Further indirect
confirmation of AAS use may be provided by the greater
FFMI observed in both AAS using groups which are vastly in
excess of the values (FFMI.25 kg/m2) proposed by Kouri et
al.22 The greater FFM values observed in both groups of AAS
using bodybuilders is consistent with the assertion that AAS
use in combination with resistance training significantly
increases lean body mass,23 which may be maintained for
prolonged periods following AAS withdrawal as shown in
postmenopausal females.24 25
The lack of discernable differences between groups in
levels of folate or B12 indicates that HCY differences were not
caused by dietary deficiencies in these nutrients. Dietary
protein intake was significantly higher amongst the AAS
using bodybuilders, mainly through the consumption of
supplementary high-protein beverages. Although HCY levels
were higher in the SU group, there was no difference in
dietary protein intake between both AAS using groups, which
suggests that diet alone is unlikely to be responsible for the
higher HCY concentrations. Investigation of vitamin B6
concentrations may have been interesting, but the specific
assay was unobtainable. Vitamin B6 concentrations would
have provided complementary data only, and for the
purposes of this study would not have affected outcomes.
In humans, the chronic effects of increased dietary methio-
nine have been investigated, whereby methionine supple-
mentation (25 mg/kg/day) for 14 days did not seem to affect
the results of a methionine loading test or fasting concentra-
tions of either methionine or HCY.26 The acute effects of a
Table 3 Male serum sex hormone data for subjects at the time of testing
SU SA BC SC Normal range
Testosterone (nmol/l) 69.4¡7.1* 17.1¡5.9 16.6¡4.9 14.0¡3.4 8–30
SHBG (nmol/l) 3.4¡2.3** 14.4¡6.4 23.7¡8.9 28.0¡12.4 15–100
FAI (%) 40.4¡28.8*** 1.6¡1.5 0.7¡0.3 0.56¡0.2 14–128
Values are means¡SD. AAS, anabolic-androgenic steroids; BC, bodybuilding controls; FAI, free androgen index; SA, AAS abstinent subjects; SC, sedentary
controls; SHBG, sex hormone binding globulin; SU, AAS using subjects.
*p,0.05, significantly different compared to SA; **p,0.01, significantly different compared to BC; ***p,0.001, significantly different compared to SC; p,0.05,
significantly lower than BC and SC.
Table 4 Test results, energy intake, and daily dietary protein intake for AAS using and control groups
SU SA BC SC
HCY (mmol/l) 13.2¡2.9** 10.4¡1.6* 8.7¡1.4 8.6¡2.1
B12 (pmol/l) 272¡176 410¡203 428¡145 290¡169
Folate (ng/ml) 7.1¡3.1 6.5¡2.1 6.5¡2.7 9.7¡3.4
Urea (mmol/l) 5.9¡2.9 5.9¡0.9 4.5¡1.7 4.2¡1.5
Creatinine (mmol/l) 107¡14.5 102¡17.2 96.1¡9.2 83.3¡13.6`
HCT (%) 55.7¡2.1** 48.2¡2.8 45.6¡2.2 43.1¡2.6
Dietary information (n = 10) (n = 10) (n = 10) (n = 10)
Energy intake (kJ/day) 18 400¡4130* 17 100¡2120* 14 900¡1725 13 440¡2140
Protein intake (g/day) 215¡70* 190¡55* 130¡25 115¡20
Values are means¡SD. BC, bodybuilding controls; SA, AAS abstinent subjects; SC, sedentary controls; SU, AAS using subjects.
*p,0.05, significantly greater than BC; **p,0.01, significantly greater than SC; p,0.01, significantly lower than SU; `p,0.05, significantly lower than SA.
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protein-rich diet involving supplemental protein drinks on
plasma HCY levels warrants further and more careful
evaluation.
Serum creatinine, regarded as an indicator of renal
function, has been shown to be a strong determinant of
plasma HCY concentration.27 28 In the present study, a weak
overall relationship was observed between creatinine and
HCY, and was only significant in the SU group (r = 0.602,
p,0.05). Creatinine concentration was significantly lower in
the control group compared with the AAS using body-
builders, and Pearson product correlation revealed a sig-
nificant relationship between creatinine and FFM (r = 0.708,
p,0.01). Given that creatinine is one of the most specific
indices of total body skeletal muscle mass29 and a marker
with low sensitivity for early decline in renal function, the
higher creatinine levels exhibited by the AAS using groups
are likely to be a function of muscle mass rather than any
renal impairment resulting from AAS consumption.
Recent clinical and epidemiological studies suggest a role
of HCY in vascular disease; tHCY is associated with intima-
media thickness in the carotid artery suggesting that this
analyte may be a marker of early carotid atherosclerosis.30 The
precise mechanism linking it to cardiovascular disease is
unknown, but it has been proposed that HCY induces
endothelial dysfunction and atherosclerosis by generation
of reactive oxygen species (ROS). Perez-de-Arce et al found
that HCY induced ROS (1.85-fold) and that expression of the
mitochondrial biogenesis factors, nuclear respiratory factor-1
and mitochondrial transcription factor A, were significantly
elevated in HCY treated cells.31 These changes were accom-
panied by an increase in mitochondrial mass and higher
mRNA and protein expression of the subunit III of
cytochrome c oxidase. These effects were significantly
prevented by pre-treatment with the antioxidants catechin
and trolox, which modulated the adverse vascular effects of
HCY.31 This may be one of the mechanisms whereby HCY can
induce vascular events. AAS have been shown to produce
marked dyslipidaemia,32 and the decrease in high density
lipoprotein cholesterol and elevation of the low density
lipoprotein cholesterol:high density lipoprotein cholesterol
ratio which is a known effect of oral ingestion of 17-a-
alylated AAS, associated with the very significant testoster-
one levels in SU compared with the other three groups, may
be another mechanism which increases the susceptibility of
the SU cohort to cardiovascular events. The AAS also increase
platelet aggregability33 34 and adversely alter endothelial func-
tion.35 Considering the lack of classic risk factors (obesity,
smoking, hypertension, inactivity), the youth of the subjects,
and the lack of atherosclerotic lesions in a number of AAS
related cardiovascular events, it is not unreasonable to suggest
atherothrombotic rather than atherogenic mechanisms for
sudden death as proposed by Ferenchick and colleagues.33 In
the absence of direct evidence, the ever-emerging case reports of
thromboembolism2 6 36–38 in AAS users provides corroborating
support for possible prothromboembolic effects of supraphy-
siological AAS administration.
In conclusion, the findings from this study suggest that the
long term use of supraphysiological doses of AAS is
associated with hyperhomocysteinaemia and dramatically
elevated HCT concentrations.
Previous research has indicated that when HCY concentra-
tions are less than 9 mm/l, there is a 3.8% increase in
mortality measured over 4.6 years. When these concentra-
tions exceed 15 mm/l, there is a 24.7% increase in mortality
measured over the same time period. In an analysis in which
patients with HCY levels below 9 mm/l were used as the
reference group, from 9–14.9 mm/l the mortality ratio was 1.9,
from 15–19.9 mm/l it was 2.8, and greater than 20 mm/l it was
4.5.10
Nygard’s work has shown that for every 5 mmol/l increase
in tHCY, the odds ratio for an increase in risk of coronary
artery disease (CAD) was 1.6 (95% confidence interval (CI),
1.4 to 1.7) for men and 1.8 (95% CI, 1.3 to 1.9) for women. A
total of 10% of the general population’s CAD risk appears
attributable to tHCY. The odds ratio for cerebrovascular
disease (5 mmol/l tHCY increment) is 1.5 (95% CI, 1.3 to 1.9).
A 5 mmol/l reduction in plasma HCY will prevent 10% of CAD
deaths in men. A 5 mmol/l tHCY increment elevates CAD risk
to the same extent as a cholesterol increase of 0.5 mmol/l.39
Additionally there have been an increasing number of case
reports of sudden death following AAS use and even mild
elevations of HCY are associated with venous thrombosis. In
the present study, three individual subjects died suddenly.
Their mean age (n = 3) was 43 years. The mean HCY value of
the SU group (n = 10) was 13.2¡2.9 mm/l. The HCY levels of
the deceased were 15, 16, and 18 mm/l. Post mortem
examination identified cardiovascular disease as a cause of
death in each case. The elevated HCY and associated HCT
levels which appear to be a consequence of AAS use cannot
be ruled out as causative in any of these cases. The findings of
this study suggest that AAS are detrimental to cardiovascular
health and appear to be implicated in cardiovascular
mortality in long term AAS abuse.
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What is already known on this topic
N AAS are known to cause marked dyslipidaemia and
there are individual case reports of sudden death
following AAS use
N Mildly increased levels of homocysteine are associated
with venous thrombosis and endothelial dysfunction
N Homocysteine levels have been shown to be elevated
by AAS use
What this study adds
N Homocysteine levels may be an easily identifiable and
powerful independent risk factor for cardiovascular
disease
N The three AAS abusers who died during this study had
elevated homocysteine levels greater than the SU
group as a whole
N The mechanism of death could be related to the
production of reactive oxygen species caused by the
elevated homocysteine, which may be attenuated by
the use of antioxidants
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